Massive Bio and FOMAT Collaborate to Enhance Cancer Patient Access to Clinical Trials
Massive Bio, a global precision oncology company, has partnered with FOMAT, the largest Embedded Research Organization in the United States, to improve cancer patient prescreening for clinical trials using AI technology. This collaboration, initiated in June 2026, aims to streamline the process of identifying eligible patients for oncology clinical trials across FOMAT's community-based research network. The partnership is currently in a pilot phase, testing the efficiency of integrating AI into the prescreening process. This initiative is designed to reduce the time between diagnosis and trial enrollment, particularly benefiting underserved communities that have historically been underrepresented in clinical research. 
